SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Serapha Bio Reports Positive Interim SERP-01 Trial Data

Serapha Bio said interim safety and efficacy data from its SERP-01 investigator-initiated trial were presented at the ERS Alpha-1 Antitrypsin Conference 2026.

Related stories